Sunday 14 July 2013

Swissmedic Approves Zonegran® (Zonisamide) Monotherapy Treatment For Epilepsy

Main Category: Epilepsy
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 12 Jul 2013 - 2:00 PDT Current ratings for:
Swissmedic Approves Zonegran® (Zonisamide) Monotherapy Treatment For Epilepsy
not yet ratednot yet rated

Zonegran(R) (zonisamide) has been approved by Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, for the monotherapy treatment of partial seizures (with or without secondary generalisation) in adults with newly diagnosed epilepsy. Monotherapy is when treatment is given with one single drug.

Already a successful add-on therapy, once-daily zonisamide is a second generation anti-epileptic drug (AED) with multiple mechanisms of action and a chemical structure which is unrelated to any other AEDs.[1] For patients with newly diagnosed epilepsy, monotherapy is the preferred option for managing their condition as this reduces the potential for adverse drug interactions and encourages treatment compliance.[2]

"Monotherapy is the optimal treatment approach for managing epilepsy and therefore the availability of zonisamide in this setting will provide newly diagnosed epilepsy patients with access to this already proven treatment as a first-line option in their care pathway," commented Professor Michel Baulac, Head of Neurology, Université Paris VI.

Epilepsy is one of the most common neurological conditions in the world[3] with an estimated 70,000 people living with the condition in Switzerland alone[4]. The successful treatment of partial-onset seizures (the most common type of epilepsy) remains a significant challenge and up to 30% of patients fail to achieve seizure freedom with existing AEDs[5].

"The approval of zonisamide monotherapy in Switzerland is a very welcome advance for both doctors and patients. The new extended monotherapy indication for Zonegran will provide patients with an alternative option to help improve their seizure control. The monotherapy indication will become an increasingly important option in the early treatment of partial epilepsy," said Dr. Christiane Kordeuter, Medical Director, Eisai Switzerland. "Zonegran is one of only six AEDs available as monotherapy, allowing doctors to tailor treatment to individual patient needs."

The efficacy and safety of zonisamide as monotherapy has been demonstrated in a double-blind, randomised, multicentre study of 583 newly diagnosed adult partial epilepsy patients, which compared the efficacy and safety of once-daily zonisamide with twice-daily controlled release carbamazepine as monotherapy. The study's primary endpoint was the proportion of seizure-free patients at six months. Zonisamide demonstrated high response rates for achieving seizure freedom in newly diagnosed patients with epilepsy,[6] similar to controlled release carbamazepine. In the majority of patients, seizure freedom was achieved at the target dose of 300 mg. Zonisamide was considered non-inferior to carbamazepine, was well tolerated and had no apparent safety concerns after one year of treatment at doses ranging from 300 to 500 mg/day.

The continued development of zonisamide underscores Eisai's human health care mission, the company's commitment to innovative solutions in disease prevention, cure and care for the health and well being of people worldwide. Eisai is committed to the therapeutic area of epilepsy and addressing the unmet medical needs of patients with epilepsy and their families. Eisai is proud to currently market more epilepsy products in EMEA than any other company.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our epilepsy section for the latest news on this subject.

1. Zonegran Summary of Product Characteristics

2. St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The Initial Approach in Epilepsy Management (2009) &(2): 77 - 72

3. ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe 2010 (Accessed June 2011)

4. EPI Swiss Epilepsy Centre (Accessed August 2011)

5. Kwan P, Brodie MJ Early identification of refractory epilepsy. New England Journal of Medicine 2000; 342:314-9

6. Baulac, M. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 11 (7) 579 - 588

Eisai

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Eisai. "Swissmedic Approves Zonegran® (Zonisamide) Monotherapy Treatment For Epilepsy." Medical News Today. MediLexicon, Intl., 12 Jul. 2013. Web.
14 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Swissmedic Approves Zonegran® (Zonisamide) Monotherapy Treatment For Epilepsy'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

No comments:

Post a Comment